Paros IBio's 'Lasmotinib' preclinical results published in research journal
Predicted impact: Low· Actual: −3.0% vs sector, volume 0.8× normal (5 trading days)
Preclinical research publication; no financial size or regulatory milestone disclosed.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.